Search Results for "Melanom Stage Iiib"
Original Source: Pegylated Interferon-Alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant melanoma in stage IIA (T3a) - IIIB. A total of 880 will be randomized up to three months after first surgical management of their melanoma to either: PEG-IFN-α-2a or low-dose interferon-α-2a.
Matching Channels
Stage IVB and recurrent cancer
CIN and squamous cell carcinoma stage IA1
Hodgkin Lymphoma is a disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be l...
Malaria represents one of the international community’s most pressing public health problems. The disease exacts an economic toll of roughly $12 billion a year in Africa. A vaccine is an ess...
In medicine, dialysis is a process for removing waste and excess water from the blood, and is primarily used to provide an artificial replacement for lost kidney function in people with renal failur...
Matching News
KYTHERA Biopharmaceuticals presents Phase IIIb study results of ATX-101
KYTHERA Biopharmaceuticals, Inc. today announced positive interim results from a Phase IIIb, multicenter, open-label study (ATX-101-11-26) of ATX-101 during the "Innovations and Renewals" session of t...
MALVERN, Pa., July 30, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb...
For Patients With Stage III Lung Cancer, Higher-Dose RT Results In Inferior Survival
In a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG), high-dose (HD), compared with standard-dose (SD), radiotherapy (RT) with concurrent chemotherapy (CT)...
Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture
Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb trial evaluating XIAFLEX for the treatment of adult Dupuytr...
Phase 2 study of REOLYSIN meets primary endpoint in patients with squamous cell lung cancer
Oncolytics Biotech Inc. today announced that it has met the primary overall statistical endpoint in its U.S. Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung usin...
Synta falls on ganetespib data
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) fell $2.51 (34%) to $4.87 on Monday after reporting median overall survival (OS) data from an interim analysis of the open-label Phase IIb portion of the inte...
Friends of Cancer Research planning lung cancer trial
Early next year, Friends of Cancer Research plans to start a Phase II/III trial of three or four investigational compounds as second-line treatments for advanced, stage IIIB or stage IV squamous cell...
PsiOxus Therapeutics Comments on Phase III Results from Amgen's Oncolytic Vaccine
LONDON--(BUSINESS WIRE)--Mar 20, 2013 - PsiOxus Therapeutics today issued a statement in response to initial results from Amgen's (Nasdaq: AMGN) phase III study of talimogene laherparepvec in patient...
Matching PubMed Articles
BACKGROUND: The objective of this retrospective study was to determine whether the current staging system for stage III colorectal cancer (CRC) is appropriate and to assess the value of the metastatic...
Background Although its efficacy is unproven, 5-fluorouracil plus cisplatin (FP) is used to prevent postoperative relapse in gastric cancer. We investigated the safety and feasibility of S-1 plus cisp...
The goal of the present study was to clarify the clinical significance of mesorectal extension in pT3 rectal cancer. This currently remains unclear. Data from 975 consecutive patients with pT3 rectal...
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
BACKGROUND: We previously reported that S-1 plus cisplatin was feasible as adjuvant chemotherapy for stage III gastric cancer after D2 gastrectomy. Herein we evaluate the recurrence-free survival and...
ABSTRACT: BACKGROUND: Recently, using a mouse model of mucopolysaccharidosis (MPS) IIIB, a lysosomal storage disease with severe neurological deterioration, we showed that MPS IIIB neuropathology is a...
